Compare Global X MSCI Argentina ETF (ARGT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X MSCI Argentina ETF vs Smith & Nephew plc — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Smith & Nephew plc trades at $30.7 (market cap $12.69B). The key difference: Smith & Nephew plc pays a 2.55% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| ARGT | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $38.70 |
52-Week Low | $67.55 | $28.73 |
Market Cap | — | $12.69B |
Enterprise Value | — | $15.46B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
Smith & Nephew (SNN) trades at $30.70, up 0.99% with a bullish technical signal supported by moving averages. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B (2024-2025) and net income margin expanding to 10.14%. Recent developments include new medical guidance publications and robotics platform advancements, while analyst consensus remains cautious with 68% hold ratings.
SNN presents a mixed outlook with strong profitability metrics and positive cash flow trends offset by recent earnings misses and conservative analyst sentiment. Investment opportunity lies in the company's medical technology innovations and margin expansion, though risks include competitive pressures and execution challenges in meeting growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
